DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Zanamivir - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antivirals
  • Enzyme Inhibitors
  • Neuraminidase Inhibitors

Dosage Forms

  • Powder

Brands / Synonyms

GANA; GNA; MODIFIED SIALIC ACID; Relenza; See Remark 8; Zanamavir ; ZMR

Indications

For the prevention and treatment of influenza

Pharmacology

Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days.

Mechanism of Action

The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Absorption

4% to 17% following an orally inhaled dose

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Not metabolized

Contraindications

RELENZA is contraindicated in patients with a known hypersensitivity to any component of the formulation.

Drug Interactions

No clinically significant pharmacokinetic drug interactions are predicted based on data from in vitro studies.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014